Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.67 |
| ▸ | BRAF | P15056 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19087056 | 0.85 | SCN10A (0.64) | GRM5BRAFCYP2C9KCNH2SCN10A | |
| SCHEMBL19077878 | 0.84 | GRM5 (0.63) | GRM5BRAF | |
| SCHEMBL19116494 | 0.84 | GRM5 (0.66) | GRM5BRAFTAS2R8 | |
| SCHEMBL27383419 | 0.82 | NPC1 (0.63) | GRM5BRAFTHRBP2RY2GPR17 | |
| SCHEMBL15847396 | 0.82 | BRAF (0.77) | GRM5BRAF | |
| SCHEMBL19087072 | 0.81 | BCAT2 (0.63) | THRBMEN1KMT2ARXFP1 | |
| SCHEMBL6926658 | 0.80 | GRM5 (1.00) | GRM5BRAF | |
| SCHEMBL19087055 | 0.80 | GRM5 (0.65) | GRM5BRAFTHRBMEN1KMT2A | |
| SCHEMBL12416743 | 0.80 | GRM5 (1.00) | GRM5 | |
| SCHEMBL5471414 | 0.80 | NT5E (0.62) | GRM5BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | GRM5 1218/4885BRAF 71/4885CYP2C9 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.